Open AccessHeterogeneity and Coexistence of T790M and T790 Wild-Type Resistant Subclones Drive Mixed Response to Third-Generation Epidermal Growth Factor Receptor Inhibitors in Lung Cancer
Author(s) -
Zofia Piotrowska,
Mehlika Hazar-Rethinam,
Caroline Rizzo,
Brandon Nadres,
Emily E. Van Seventer,
Heather A. Shahzade,
Inga T. Lennes,
A. John Iafrate,
Dora DiasSantagata,
Ignaty Leshchiner,
Nicholas A. Jessop,
Haichuan Hu,
Subba R. Digumarthy,
Rebecca J. Nagy,
Richard B. Lanman,
Susan E. Moody,
Matthew J. Niederst,
Jeffrey A. Engelman,
Aaron N. Hata,
Ryan B. Corcoran,
Lecia V. Sequist
Publication year - 2018
Publication title -
jco precision oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.405
H-Index - 22
ISSN - 2473-4284
DOI - 10.1200/po.17.00263
Subject(s) - t790m , epidermal growth factor receptor , digital polymerase chain reaction , somatic evolution in cancer , biology , cancer research , mutation , lung cancer , epidermal growth factor , lung , polymerase chain reaction , receptor , cancer , genetics , pathology , medicine , gefitinib , gene
Third-generation epidermal growth factor receptor (EGFR) inhibitors like nazartinib are active against EGFR mutation-positive lung cancers with T790M-mediated acquired resistance to initial anti-EGFR treatment, but some patients have mixed responses.